News & Updates

Social isolation tied to detrimental outcomes in CKD

01 Jun 2025

For patients with chronic kidney disease (CKD) who are facing social isolation, survival is shortened while the onset of cardiovascular disease is accelerated, as shown in a prospective cohort study.

Social isolation tied to detrimental outcomes in CKD

01 Jun 2025

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

31 May 2025 by

Cytisinicline’s efficacy and tolerability for smoking cessation has been validated in another large phase III trial conducted in the US, with both the 6- and 12-week treatments yielding positive benefits persisting through 24 weeks.

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

31 May 2025

Internal tremors, vibrations pester people with long COVID

31 May 2025 by

Individuals with long COVID may experience internal tremors and vibrations, which can signal a worse health status compared with others without these symptoms, a study has shown.

Internal tremors, vibrations pester people with long COVID

31 May 2025

2-year changes in remnant cholesterol predictive of stroke

31 May 2025

Substantial changes in remnant cholesterol levels over time are associated with a heightened risk of stroke in the general population, according to a study.

2-year changes in remnant cholesterol predictive of stroke

31 May 2025

Adult-onset Still’s disease outcomes better with frontline biological vs csDMARD therapy

30 May 2025

In the first-line treatment of patients with adult-onset Still’s disease (AOSD), biological disease-modifying antirheumatic drug (DMARD) therapy is associated with increased likelihood of achieving sustained, event-free remission in addition to fewer complications compared with conventional synthetic (cs) DMARDs, according to a study from Germany.

Adult-onset Still’s disease outcomes better with frontline biological vs csDMARD therapy

30 May 2025

Even low-risk diabetes patients obtain renal, mortality benefits with SGLT2 inhibitors

30 May 2025 by

Sodium-glucose cotransporter-2 (SGLT2) inhibitors help reduce the risk of lung function decline and mortality in a low-risk population of patients with type 2 diabetes (T2D) who have normal or low BMI, as shown in a single-centre retrospective study from Korea.

Even low-risk diabetes patients obtain renal, mortality benefits with SGLT2 inhibitors

30 May 2025

Aspirin offers no protection against cardiac events in asymptomatic coronary stenosis

30 May 2025

Asymptomatic individuals with incidentally diagnosed coronary artery stenosis may forego the use of aspirin, with a recent study suggesting that it does not provide any significant benefit for the prevention of composite events and bleeding.

Aspirin offers no protection against cardiac events in asymptomatic coronary stenosis

30 May 2025

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

30 May 2025 by

Patients with extensive-stage small cell lung cancer (ES-SCLC) derive real-world clinical benefits from first-line treatment with atezolizumab combined with carboplatin and etoposide (CP/ET), reports a recent study.

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

30 May 2025

Low- better than high-intensity resistance exercise in lowering BP

30 May 2025

Low-intensity resistance exercise, compared with a high-intensity session, more effectively reduces blood pressure (BP) in patients with hypertension, a study has shown.

Low- better than high-intensity resistance exercise in lowering BP

30 May 2025

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

30 May 2025 by

Findings from the phase III ELATIVE^® trial demonstrate that the peroxisome proliferator-activated receptor (PPAR) agonist elafibranor improves fatigue in individuals with primary biliary cholangitis (PBC), with limited correlation with pruritus.

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

30 May 2025

News & Updates

Filter by Specialty:

Specialty:

Social isolation tied to detrimental outcomes in CKD

Social isolation tied to detrimental outcomes in CKD

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

Internal tremors, vibrations pester people with long COVID

Internal tremors, vibrations pester people with long COVID

2-year changes in remnant cholesterol predictive of stroke

2-year changes in remnant cholesterol predictive of stroke

Adult-onset Still’s disease outcomes better with frontline biological vs csDMARD therapy

Adult-onset Still’s disease outcomes better with frontline biological vs csDMARD therapy

Even low-risk diabetes patients obtain renal, mortality benefits with SGLT2 inhibitors

Even low-risk diabetes patients obtain renal, mortality benefits with SGLT2 inhibitors

Aspirin offers no protection against cardiac events in asymptomatic coronary stenosis

Aspirin offers no protection against cardiac events in asymptomatic coronary stenosis

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

Low- better than high-intensity resistance exercise in lowering BP

Low- better than high-intensity resistance exercise in lowering BP

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients